Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zevalin for Post-Transplant Relapsed B-Cell Non-Hodgkin's Lymphoma
NCT00031642Phase 2Completed
- Sponsor
- University of Nebraska
- Start
- Jan 2002
- Primary completion
- Nov 2005
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ibritumomab tiuxetan in B-cell non-Hodgkin lymphoma (B-NHL), sponsored by University of Nebraska. Primary endpoints: Maximum Tolerated Dose, Safety and 1 more. Started Jan 2002; status: completed.
02
Drugs
ibritumomab tiuxetan
03
Conditions
B-cell non-Hodgkin lymphoma (B-NHL)
Beyond the preview
Go deeper on NCT00031642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00031642.